Crescent Biopharma CBIO Institutional Ownership

Crescent Biopharma, Inc. (NASDAQ:CBIO) has 84 institutional investors that have filed 13F reports for the period ending June 2026.

• Collectively, these holders controlled 97.1% of Crescent Biopharma's outstanding shares in June 2026, up from 85.4% in March 2026.
• They increased total shares held in Crescent Biopharma by 22.38% from last quarter, and the number of investors in CBIO increased 180.0% annually.
• During the quarter, 51 of these 84 funds increased positions in CBIO, 15 reduced exposure, and 18 held steady.
• Altogether, these fund groups held 29.64Mn shares in CBIO by June 2026, up by 5.42Mn shares quarter on quarter, and up 18.45Mn shares year over year.
• As of June 30, 2026, FMR LLC held the largest stake in Crescent Biopharma with 4.13Mn shares, accounting for 13.54% of total shares outstanding.
• The biggest buyers of Crescent Biopharma for the quarter ending June 2026 included Logos Global Management LP (1.42Mn), BlackRock, Inc. (1.16Mn), Remedium Capital Partners, LLC (361.25K), Ameriprise Financial Inc (302.57K), GEODE CAPITAL MANAGEMENT, LLC (280.36K).
• The largest sellers of Crescent Biopharma for the quarter ending June 2026 were SILVERARC CAPITAL MANAGEMENT, LLC (71.4K), Stonepine Capital Management, LLC (45.0K), VANGUARD CAPITAL MANAGEMENT LLC (33.64K), ADAR1 Capital Management, LLC (32.0K), Jpmorgan Chase & Co (31.98K).
• Business Quant data shows the 10 biggest positions in Crescent Biopharma as of June 2026 are held by FMR LLC (4.13Mn), BVF INC/IL (2.75Mn), Fairmount Funds Management LLC (2.75Mn), Venrock Adviser, LLC (2.13Mn), Logos Global Management LP (1.9Mn), FCPM III SERVICES B.V. (1.68Mn), BALYASNY ASSET MANAGEMENT L.P. (1.66Mn), Vestal Point Capital, LP (1.63Mn), Opaleye Management Inc. (1.32Mn), BlackRock, Inc. (1.27Mn).